Skin Pigmentation Disorders
Also known as: Hyperpigmentation, Hypopigmentation, Dyschromia, Ephelis
Methodology & AI Transparency ⓘ
Skin Pigmentation Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Pigmentation means coloring.
- 2 Real-world patient consensus: Clinical coding for Skin Pigmentation Disorders uses ICD-10 L81.9 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Clinicians assessing Skin Pigmentation Disorders focus on cutaneous immune skewing in Skin Pigmentation Disorders (L81.9: (Th2/IL-4/IL-13 in atopic) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Skin Pigmentation Disorders monitoring tracks Fasting Lipids & in Skin Pigmentation Disorders (L81.9: ALT (if systemic) toward Within baseline reference limits (L81.9).
Ask our AI Specialists anything about Skin Pigmentation Disorders
What Is Skin Pigmentation Disorders?
Pigmentation means coloring. Skin pigmentation disorders affect the color of your skin. Your skin gets its color from a pigment called melanin. Special cells in the skin make melanin. When these cells become damaged or unhealthy, it affects melanin production. Some pigmentation disorders affect just patches of skin. Others affect your entire body. If your body makes too much melanin, your skin gets darker. Pregnancy, Addison's disease, and sun exposure all can make your skin darker. If your body makes too little melanin, your skin gets lighter. Vitiligo is a condition that causes patches of light skin. Albinism is a genetic condition affecting a person's skin.
Pathophysiology, Underlying Causes & Clinical Presentation
In Skin Pigmentation Disorders (L81.9), physiological disruption stems from cutaneous immune skewing in Skin Pigmentation Disorders (L81.9: (Th2/IL-4/IL-13 in atopic), Cross-referenced with NIH MeSH (Pigmentation Disorders), informing Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols that track 25-Hydroxy Vitamin D in Skin Pigmentation Disorders (L81.9: & hs-CRP) (25(OH)D 40–65 ng/mL (L81.9)).
Common Symptoms & Clinical Signs
- • Presentation of Skin Pigmentation Disorders (L81.9): recurrent flares triggered in Skin Pigmentation Disorders (L81.9: by UV exposure,)
- • Secondary Skin Pigmentation Disorders clinical sign: persistent erythematous plaques, in Skin Pigmentation Disorders (L81.9: scaly patches, pruritic)
- • Symptom flares in Skin Pigmentation Disorders correlating with Fasting Lipids & in Skin Pigmentation Disorders (L81.9: ALT (if systemic) deviation outside Within baseline reference limits (L81.9)
- • Functional skin & dermatology impact requiring dermoscopy or punch in Skin Pigmentation Disorders (L81.9: biopsy when atypical) evaluation (L81.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Skin Pigmentation Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L81.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Skin Pigmentation Disorders (L81.9: ALT (if systemic) | Within baseline reference limits (L81.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Skin Pigmentation Disorders (L81.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (L81.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Skin Pigmentation Disorders (L81.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L81.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Skin Pigmentation Disorders
Treatment selection for Skin Pigmentation Disorders depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Skin Pigmentation Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients: What a 1,614-Participant Study Found Once-daily treatment with tazarotene 0.045% polymeric emulsion lotion may help improve patient-perceived skin oiliness in those with moderate-to-severe acne. The Journal of dermatological treatment • 2023-12-15 • Randomized Controlled Trial | N = 1,614 | 96/100 | PMID 36382987 ↗ |
| New Insights on Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy: What a 1,564-Participant Study Found The diagnostic performance of the EC skin test was similar to that of the T-SPOT test in the healthy population and was unaffected by BCG vaccination. BMC infectious diseases • 2024-12-30 • Phase III Randomized Trial | N = 1,564 | 96/100 | PMID 39736611 ↗ |
| New Insights on Incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic: What a 259-Participant Study Found The incidence of TD was relatively low in both younger and older patients with depression with psychotic features treated acutely with olanzapine. Journal of clinical psychopharmacology • 2013-06-15 • Randomized Controlled Trial | N = 259 | 93/100 | PMID 23609383 ↗ |
| New Insights on Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients: What a 564-Participant Study Found LEB was associated with high rates of durable absolute EASI response, even in cases of high baseline severity or suboptimal week-16 outcomes. Acta dermato-venereologica • 2026-05-21 • Phase III Randomized Trial | N = 564 | 93/100 | PMID 42163822 ↗ |
| New Insights on Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute: What a 335-Participant Study Found TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-10-05 • Phase III Randomized Trial | N = 335 | 93/100 | PMID 32897367 ↗ |
Skin Pigmentation Disorders Patient Community & “People Like Me” Threads
Filter Skin Pigmentation Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.